Abstract 1945P
Background
Soft tissue sarcomas (STS) are a group of rare heterogeneous mesenchymal tumours with distinct clinical and molecular features. Current therapeutic approaches in advanced STS are limited to conventional chemotherapy and targeted therapy without significant impact on survival. Liquid biopsy (LB) or cell-free DNA is an innovative tool in cancer practice that detects particular molecular alterations (MA) with diagnostic and therapeutic implications. In this case series, we report the outcomes of LB in a cohort of international STS patients.
Methods
In this prospective cohort, all STS patients from the international department treated in Gustave Roussy Cancer Campus that underwent a LB during their disease course between 01/2022 and 03/2023 were included. Demographic data were gathered with various significant MA.
Results
18 STS patients were included in this series with a median age of 49 yrs. 9 were men (50%) and all patients had inoperable or metastatic disease at the time of LB. They had a median of 1 prior line of therapy. Three patients had a high TMB (tumour mutational burden) (16.6%) with more than 10 mut/mb. Four patients (22.2%) had targetable MA: Three pts had MSI-high tumors (microsatellite instability, two uterine leiomyosarcoma and 1 with GIST) with high sensitivity to immune checkpoint inhibitors and 1 angiosarcoma patient had BRAF mutation in which a BRAF and MEK inhibitors were introduced. On the other hand, four patients had confirmed STS diagnosis with the detection of fusion transcripts: two had Ewing sarcoma, one had desmoplastic round cell tumour and one patient had the EWSR1-ATF1 fusion transcript which helped changing the diagnosis from suspected melanoma to clear cell sarcoma. Also four patients had genetic counselling after detecting germline mutations (2 NF1 in GIST and MPNST, 1 APC in desmoid tumor and 1 POLD1 in chondrosarcoma). Two patients benefited from haematology referral after confirmed JAK2 mutations.
Conclusions
LB proved to be an attractive technique to detect significant MA in advanced STS, a group of malignant tumors with a challenging diagnosis and therapeutic approach. This tool can be implemented as an adjunct tool to offer novel therapeutic options to patients as well as fine-tuning of the diagnostic process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15